ACS chemical neuroscience molecule spotlight on savella

Research output: Contribution to journalShort survey

Abstract

Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.

Original languageEnglish (US)
Number of pages1
JournalACS Chemical Neuroscience
Volume1
Issue number5
DOIs
StatePublished - May 19 2010

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on savella'. Together they form a unique fingerprint.

  • Cite this